Beigene-283 is primarily utilized in the field of oncology as a targeted therapeutic agent. It is designed to inhibit specific signaling pathways that are crucial for the survival and proliferation of cancer cells. This makes it particularly effective in treating certain types of cancers where these pathways are dysregulated. The compound is often used in clinical trials to evaluate its efficacy and safety in patients with advanced or refractory cancers. Additionally, Beigene-283 is being studied for its potential to enhance the effectiveness of other cancer treatments, such as chemotherapy and immunotherapy, by sensitizing cancer cells to these therapies. Its application is focused on improving patient outcomes and providing new treatment options for difficult-to-treat malignancies.